{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:49:50Z","timestamp":1794962990291,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The trial was funded by MoonLake Immunotherapeutics AG, Zug, Switzerland, who participated in the collection, analysis, and interpretation of data."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Psoriatic arthritis (PsA) is a progressive, multidomain and interleukin-17 (IL-17)-linked disease that results in substantial quality-of-life deficits. Thereby, we conducted a phase 2 randomized, double-blind, placebo (PBO)-controlled trial of sonelokimab (SLK), a nanobody that binds with a similarly high affinity to IL-17A and IL-17F, inhibiting all dimers. Overall, 207 patients with active PsA were randomized to SLK 120-mg or 60-mg every 4 weeks (Q4W; both with induction (WI)), or to 60-mg Q4W with no induction, PBO or adalimumab (reference arm). The primary endpoint of American College of Rheumatology (ACR) 50 at week 12 was met for SLK 60-mg and 120-mg WI (60-mg WI\u2009=\u200946.3% (19\/41; odds ratio (OR)\u2009=\u20093.6; 95% confidence interval (CI)\u2009=\u20091.3\u20139.9;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05); 120-mg WI\u2009=\u200946.5% (20\/43; OR\u2009=\u20094.0; 95% CI\u2009=\u20091.4\u201311.3;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) versus PBO\u2009=\u200920.0% (8\/40)). SLK resulted in significant benefits across the key secondary endpoints of ACR20 (60-mg WI\u2009=\u200978.0% (32\/41;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and 120-mg WI\u2009=\u200972.1% (31\/43;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002) versus PBO\u2009=\u200937.5% (15\/40)) and Psoriasis Area and Severity Index (PASI) 90 at week 12 (60-mg WI\u2009=\u200976.9% (20\/26;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and 120-mg WI\u2009=\u200959.3% (16\/27;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.003) versus PBO\u2009=\u200915.4% (4\/26)). Robust responses were observed among patients randomized to SLK at week 24 for the high-threshold composite endpoints of ACR70\u2009+\u2009PASI 100 (exploratory) and minimal disease activity (secondary), achieved by up to 48% (13\/27; 120-mg WI) and 61% (25\/41; 60-mg WI), respectively. SLK was well-tolerated; the most common treatment-emergent adverse events were nasopharyngitis (60 mg\u2009=\u20096.1%; 120 mg\u2009=\u20095.2%), upper respiratory tract infection (60 mg\u2009=\u20096.1%; 120 mg\u2009=\u20094.1%), injection-site erythema (60 mg\u2009=\u20093.7%; 120 mg\u2009=\u20093.1%) and headache (60 mg\u2009=\u20092.4%; 120 mg\u2009=\u20094.1%). Four cases of mild to moderate oral candidiasis occurred (60 mg\u2009=\u20092.4%; 120 mg\u2009=\u20092.1%). Overall, SLK delivered substantial improvements in the signs and symptoms of PsA across various outcomes and domains. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05640245\" ext-link-type=\"uri\">NCT05640245<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-03971-6","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:04:34Z","timestamp":1759741474000},"page":"4160-4171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuala","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Godwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"3971_CR1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J. & Moots, R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann. Rheum. Dis. 78, 1167\u20131178 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"3971_CR2","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"3759","author":"A Ogdie","year":"2020","unstructured":"Ogdie, A., Coates, L. C. & Gladman, D. D. Treatment guidelines in psoriatic arthritis. Rheumatology 3759, i37\u2013i46 (2020).","journal-title":"Rheumatology"},{"key":"3971_CR3","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes, I. B. et al. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open 8, e002074 (2022).","journal-title":"RMD Open"},{"key":"3971_CR4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40744-022-00436-x","volume":"9","author":"A Ogdie","year":"2022","unstructured":"Ogdie, A. et al. Experiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower registry. Rheumatol. Ther. 9, 735\u2013751 (2022).","journal-title":"Rheumatol. Ther."},{"key":"3971_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105534","volume":"90","author":"JA Walsh","year":"2023","unstructured":"Walsh, J. A. et al. Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine 90, 105534 (2023).","journal-title":"Joint Bone Spine"},{"key":"3971_CR6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68, 1060\u20131071 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"3971_CR7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann. Rheum. Dis. 83, 706 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"3971_CR8","unstructured":"Ogdie, A. et al. Impact of achieving minimal disease activity on patient-reported outcome measures and disease activity among patients with psoriatic arthritis treated with biologic and targeted synthetic DMARDs (abstract). Arthritis Rheumatol. 73, (2021)."},{"key":"3971_CR9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/rheumatology\/key203","volume":"57","author":"F Behrens","year":"2018","unstructured":"Behrens, F. et al. Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab. Rheumatology 57, 1938\u20131946 (2018).","journal-title":"Rheumatology"},{"key":"3971_CR10","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1136\/rmdopen-2019-001002","volume":"5","author":"LC Coates","year":"2019","unstructured":"Coates, L. C. et al. Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open 5, e001002 (2019).","journal-title":"RMD Open"},{"key":"3971_CR11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","volume":"47","author":"M Zardin-Moraes","year":"2020","unstructured":"Zardin-Moraes, M. et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis. J. Rheumatol. 47, 839\u2013846 (2020).","journal-title":"J. Rheumatol."},{"key":"3971_CR12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","volume":"19","author":"A Najm","year":"2023","unstructured":"Najm, A., Goodyear, C. S., McInnes, I. B. & Siebert, S. Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nat. Rev. Rheumatol. 19, 153\u2013165 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"3971_CR13","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","volume":"62","author":"J Leipe","year":"2010","unstructured":"Leipe, J. et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 62, 2876\u20132885 (2010).","journal-title":"Arthritis Rheum."},{"key":"3971_CR14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri, S. P., Raychaudhuri, S. K. & Genovese, M. C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol. Cell. Biochem. 359, 419\u2013429 (2012).","journal-title":"Mol. Cell. Biochem."},{"key":"3971_CR15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5152\/eurjrheum.2017.17037","volume":"4","author":"EA Wang","year":"2017","unstructured":"Wang, E. A., Suzuki, E., Maverakis, E. & Adamopoulos, I. E. Targeting IL-17 in psoriatic arthritis. Eur. J. Rheumatol. 4, 272\u2013277 (2017).","journal-title":"Eur. J. Rheumatol."},{"key":"3971_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt, S. et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann. Rheum. Dis. 77, 523\u2013532 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"3971_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham, B. W., Kavanaugh, A. & Reich, K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 141, 133\u2013142 (2014).","journal-title":"Immunology"},{"key":"3971_CR18","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","volume":"2","author":"IB McInnes","year":"2020","unstructured":"McInnes, I. B. et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol. 2, e227\u2013e235 (2020).","journal-title":"Lancet Rheumatol."},{"key":"3971_CR19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","volume":"33","author":"J Reis","year":"2019","unstructured":"Reis, J., Vender, R. & Torres, T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs 33, 391\u2013399 (2019).","journal-title":"BioDrugs"},{"key":"3971_CR20","doi-asserted-by":"crossref","first-page":"10305","DOI":"10.3390\/ijms241210305","volume":"24","author":"G Sanchez-Rodriguez","year":"2023","unstructured":"Sanchez-Rodriguez, G. & Puig, L. Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies. Int. J. Mol. Sci. 24, 10305 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"3971_CR21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","volume":"16","author":"LG Van Baarsen","year":"2014","unstructured":"Van Baarsen, L. G. et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res. Ther. 16, 426 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"3971_CR22","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","volume":"181","author":"JF Wright","year":"2008","unstructured":"Wright, J. F. et al. The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex. J. Immunol. 181, 2799\u20132805 (2008).","journal-title":"J. Immunol."},{"key":"3971_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich, K. et al. Bimekizumab versus secukinumab in plaque psoriasis. N. Engl. J. Med. 385, 142\u2013152 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3971_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola, J. F. et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 401, 38\u201348 (2023).","journal-title":"Lancet"},{"key":"3971_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes, I. B. et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 401, 25\u201337 (2023).","journal-title":"Lancet"},{"key":"3971_CR26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/rheumatology\/39.10.1139","volume":"39","author":"EH Choy","year":"2000","unstructured":"Choy, E. H. et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology 39, 1139\u20131146 (2000).","journal-title":"Rheumatology"},{"key":"3971_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrrheum.2013.159","volume":"10","author":"CH Evans","year":"2014","unstructured":"Evans, C. H., Kraus, V. B. & Setton, L. A. Progress in intra-articular therapy. Nat. Rev. Rheumatol. 10, 11\u201322 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"3971_CR28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.1780140503","volume":"14","author":"I Kushner","year":"1971","unstructured":"Kushner, I. & Somerville, J. A. Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum. 14, 560\u2013570 (1971).","journal-title":"Arthritis Rheum."},{"key":"3971_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jovcevska","year":"2020","unstructured":"Jovcevska, I. & Muyldermans, S. The therapeutic potential of Nanobodies. BioDrugs 34, 11\u201326 (2020).","journal-title":"BioDrugs"},{"key":"3971_CR30","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","volume":"7","author":"BM Tijink","year":"2008","unstructured":"Tijink, B. M. et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody Technology. Mol. Cancer Ther. 7, 2288\u20132297 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"3971_CR31","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","volume":"8","author":"P Bannas","year":"2017","unstructured":"Bannas, P., Hambach, J. & Koch-Nolte, F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front. Immunol. 8, 1603 (2017).","journal-title":"Front. Immunol."},{"key":"3971_CR32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"3971_CR33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","volume":"8","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Influence of molecular size on tissue distribution of antibody fragments. MAbs 8, 113\u2013119 (2016).","journal-title":"MAbs"},{"key":"3971_CR34","volume":"12","author":"S Oyama","year":"2022","unstructured":"Oyama, S. et al. A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Sci. Rep. 12, 18102 (2022).","journal-title":"Sci. Rep."},{"key":"3971_CR35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp, K. A., Weinberg, M. A., Morris, A. & Reich, K. IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet 397, 1564\u20131575 (2021).","journal-title":"Lancet"},{"key":"3971_CR36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","volume":"81","author":"D Svecova","year":"2019","unstructured":"Svecova, D. et al. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A\/F nanobody, in moderate-to-severe psoriasis. J. Am. Acad. Dermatol. 81, 196\u2013203 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3971_CR37","unstructured":"Kimball, A. B. et al. Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody\u00ae sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): week 24 results from the Phase 2 MIRA trial (abstract 56014). In Proc. American Academy of Dermatology Annual Meeting abstr. 56014 (2024)."},{"key":"3971_CR38","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","volume":"67","author":"J Belasco","year":"2015","unstructured":"Belasco, J. et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. 67, 934\u2013944 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"3971_CR39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","volume":"7","author":"JS Smolen","year":"2020","unstructured":"Smolen, J. S. et al. Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study. Rheumatol. Ther. 7, 1021\u20131035 (2020).","journal-title":"Rheumatol. Ther."},{"key":"3971_CR40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","volume":"42","author":"AM Orbai","year":"2016","unstructured":"Orbai, A. M. & Ogdie, A. Patient-reported outcomes in psoriatic arthritis. Rheum. Dis. Clin. North Am. 42, 265\u2013283 (2016).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"3971_CR41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3899\/jrheum.161459","volume":"44","author":"W Tillett","year":"2017","unstructured":"Tillett, W. et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J. Rheumatol. 44, 1445\u20131452 (2017).","journal-title":"J. Rheumatol."},{"key":"3971_CR42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41927-018-0030-y","volume":"2","author":"LC Coates","year":"2018","unstructured":"Coates, L. C. et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients\u2019 health-related quality of life and productivity. BMC Rheumatol. 2, 24 (2018).","journal-title":"BMC Rheumatol."},{"key":"3971_CR43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329\u20131339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3971_CR44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease, P. J. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann. Rheum. Dis. 76, 79\u201387 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"3971_CR45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 18, 465\u2013479 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"3971_CR46","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease, P. J. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279\u20133289 (2005).","journal-title":"Arthritis Rheum."},{"key":"3971_CR47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes, I. B. et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N. Engl. J. Med. 384, 1227\u20131239 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3971_CR48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2023.03.035","volume":"152","author":"S Cole","year":"2023","unstructured":"Cole, S. et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J. Allergy Clin. Immunol. 152, 783\u2013798 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3971_CR49","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kead705","volume":"63","author":"PJ Mease","year":"2024","unstructured":"Mease, P. J. et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology 63, 1779\u20131789 (2024).","journal-title":"Rheumatology"},{"key":"3971_CR50","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams, R. et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front. Immunol. 11, 1894 (2020).","journal-title":"Front. Immunol."},{"key":"3971_CR51","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.21827","volume":"54","author":"K Coppieters","year":"2006","unstructured":"Coppieters, K. et al. Formatted anti-tumor necrosis factor \u03b1 VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 54, 1856\u20131866 (2006).","journal-title":"Arthritis Rheum."},{"key":"3971_CR52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","volume":"78","author":"MG Lebwohl","year":"2018","unstructured":"Lebwohl, M. G. et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J. Am. Acad. Dermatol. 78, 81\u201389 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3971_CR53","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137\u20131146 (2015).","journal-title":"Lancet"},{"key":"3971_CR54","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Front. Immunol. 14, 993057 (2023).","journal-title":"Front. Immunol."},{"key":"3971_CR55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41590-018-0134-y","volume":"19","author":"C Tang","year":"2018","unstructured":"Tang, C. et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat. Immunol. 19, 755\u2013765 (2018).","journal-title":"Nat. Immunol."},{"key":"3971_CR56","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/MIB.0b013e318286fa1c","volume":"19","author":"EG Wedebye Schmidt","year":"2013","unstructured":"Wedebye Schmidt, E. G. et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm. Bowel Dis. 19, 1567\u20131576 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"3971_CR57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155715","volume":"148","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Divergent functions of IL-17-family cytokines in DSS colitis: insights from a naturally-occurring human mutation in IL-17F. Cytokine 148, 155715 (2021).","journal-title":"Cytokine"},{"key":"3971_CR58","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson, L. et al. Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources. Lancet Reg. Health Eur. 13, 100266 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"3971_CR59","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/ph15111365","volume":"15","author":"V Eshwar","year":"2022","unstructured":"Eshwar, V., Kamath, A., Shastry, R., Shenoy, A. K. & Kamath, P. A review of the safety of interleukin-17A inhibitor secukinumab. Pharmaceuticals 15, 1365 (2022).","journal-title":"Pharmaceuticals"},{"key":"3971_CR60","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb, A. B. et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm. Venereol. 102, adv00698 (2022).","journal-title":"Acta Derm. Venereol."},{"key":"3971_CR61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","volume":"26","author":"A Deodhar","year":"2024","unstructured":"Deodhar, A. et al. Long-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Res. Ther. 26, 49 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"3971_CR62","doi-asserted-by":"crossref","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","volume":"102","author":"K Reich","year":"2022","unstructured":"Reich, K. et al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. Acta Derm. Venereol. 102, adv00683 (2022).","journal-title":"Acta Derm. Venereol."},{"key":"3971_CR63","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","volume":"5","author":"L Eder","year":"2023","unstructured":"Eder, L. et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 5, e716\u2013e727 (2023).","journal-title":"Lancet Rheumatol."},{"key":"3971_CR64","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","volume":"9","author":"L Eder","year":"2022","unstructured":"Eder, L. et al. Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials. Rheumatol. Ther. 9, 919\u2013933 (2022).","journal-title":"Rheumatol. Ther."},{"key":"3971_CR65","unstructured":"Wright, G. et al. Comparison of secukinumab versus adalimumab efficacy by sex in psoriatic arthritis from a phase 3b, double-blinded, randomized, active-controlled study (abstract). Arthritis Rheumatol. 72, (2020)."},{"key":"3971_CR66","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/rheumatology\/keae558","volume":"63","author":"PS Helliwell","year":"2024","unstructured":"Helliwell, P. S. Axial involvement in psoriatic arthritis: is it unique? Rheumatology 63, ii15\u2013ii19 (2024).","journal-title":"Rheumatology"},{"key":"3971_CR67","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson, D. T. et al. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727\u2013735 (1995).","journal-title":"Arthritis Rheum."},{"key":"3971_CR68","first-page":"859","volume":"50","author":"CS Carlin","year":"2004","unstructured":"Carlin, C. S., Feldman, S. R., Krueger, J. G., Menter, A. & Krueger, G. G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J. Am. Acad. Dermatol. 50, 859\u2013866 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3971_CR69","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec, L. et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann. Rheum. Dis. 73, 1012\u20131019 (2014).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03971-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03971-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03971-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:13Z","timestamp":1765814413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03971-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3971"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03971-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.B.M. has received consultancy and\/or research income from AbbVie, Absci, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Causeway Therapeutics, Cabaletta, Compugen, Dextera, Eli Lilly, Gilead, Janssen, Novartis, Montai, MoonLake Immunotherapeutics AG, Pfizer, Roche, Recludix, Sanofi and UCB; is a board member on the NHS GGC (nonexecutive role); holds trustee status at Versus Arthritis (nonexecutive role) and is a stockholder of Cabaletta, Causeway Therapeutics, Compugen and Dextera. L.C.C. has received grants\/research support from AbbVie, Amgen, Janssen and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Enlivex, Janssen, MoonLake Immunotherapeutics AG, Novartis, Pfizer, Takeda and UCB and has been paid as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB. P.J.M. has received consultancy fees from AbbVie, Acelyrin, Amgen, BMS, Century, Cullinan Biotech, Eli Lilly, Inmagene, Johnson & Johnson, MoonLake Immunotherapeutics AG, Novartis, Pfizer, Takeda and UCB; has received grants or contracts from AbbVie, Amgen, Acelyrin, BMS, Eli Lilly, Johnson & Johnson, Novartis, Pfizer and UCB; payments or honoraria from AbbVie, Amgen, Eli Lilly, Johnson & Johnson, Novartis, Pfizer and UCB; has participated on a safety monitoring board at Genascence and holds a leadership or fiduciary role at GRAPPA, OMERACT and SpartAN. A.O. has received consulting fees from AbbVie, Amgen, BMS, Celgene, CorEvitas, Eli Lilly, Gilead, Janssen, Kopa\/Twill Health, Novartis, Pfizer, Spyre, Takeda and UCB, and received grants\/research support from AbbVie (to Penn), Amgen (to Forward\/NDB), BMS (to Forward), Forward Databank, Janssen (to Penn), NIH\/NIAMS, National Psoriasis Foundation, Novartis (to Penn), Pfizer (to Penn), Rheumatology Research Foundation and UCB (to Penn). A. Kavanaugh has received consultancy fees from BMS, Eli Lilly, Janssen, MoonLake Immunotherapeutics AG, Pfizer, Takeda and UCB. L.E. has received consultancy fees from BMS and received grants from and participated on advisory boards for AbbVie, Eli Lilly, Johnson & Johnson, Novartis and UCB. G.S. has received speaker bureau fees from Cabaletta, Eli Lilly, Janssen, Kyverna, Novartis and UCB. A. Kivitz has received consultancy fees from AbbVie, Coval, Ecor1, Fresenius Kabi, Gilead, Gr\u00fcnenthal, GSK, Halia, Horizon, Innovaderm, Janssen, MoonLake Immunotherapeutics AG, Pacira, Prometheus, Santa Ana Bio, Synact, Takeda\u2013Nimbus, UCB, VYNE, XBiotech and Xencor; speaker and\/or speaker bureau fees from AbbVie, GSK, Sanofi\u2013Regeneron and UCB; has received advisory board fees from Fresenius Kabi, Janssen, Takeda\u2013Nimbus and UCB; has received scientific expert fees from Genzyme; educational fees from Prime and is a stockholder of Amgen, Gilead, GSK, Novartis and Pfizer. D.M. has received grants\/research support from AbbVie, Celgene, Janssen, Merck, MoonLake Immunotherapeutics AG, Pfizer, Novartis and Sobi; has received honoraria\/consultancy fees from AbbVie, Celgene, Janssen, Merck, Novartis, MoonLake Immunotherapeutics AG, Pfizer, Sobi and UCB and participated in speaker\u2019s bureau for AbbVie, Celgene, Janssen, Merck, Novartis, MoonLake Immunotherapeutics AG, Pfizer, Sobi and UCB. N.B., A.G. and E.C. are employees of, and may be stockholders of, MoonLake Immunotherapeutics AG. K.R. has served as an advisor and\/or paid speaker for and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, Galderma, Janssen-Cilag, Kyowa Kirin, LEO Pharma, medac, Novartis, Ocean Pharma, Pfizer, Sanofi and UCB, and is also an employee and stockholder of MoonLake Immunotherapeutics AG. C.T.R. has received consulting fees from AbbVie, Johnson & Johnson and UCB; receiving payment or honoraria from Eli Lilly for lectures and received grant\/research support from BMS, Johnson & Johnson, Novartis and UCB. J.F.M. has acted as a consultant and\/or investigator for AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, BMS, Dermavant, Eli Lilly, Janssen, MoonLake Immunotherapeutics AG, Novartis, Oruka Therapeutics, Pfizer, Sanofi, Sun Pharma, Regeneron and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}